Ursula McGovern

4.0k total citations
15 papers, 459 citations indexed

About

Ursula McGovern is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Ursula McGovern has authored 15 papers receiving a total of 459 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Pulmonary and Respiratory Medicine, 7 papers in Oncology and 6 papers in Surgery. Recurrent topics in Ursula McGovern's work include Bladder and Urothelial Cancer Treatments (4 papers), Prostate Cancer Treatment and Research (4 papers) and PARP inhibition in cancer therapy (4 papers). Ursula McGovern is often cited by papers focused on Bladder and Urothelial Cancer Treatments (4 papers), Prostate Cancer Treatment and Research (4 papers) and PARP inhibition in cancer therapy (4 papers). Ursula McGovern collaborates with scholars based in United Kingdom, Spain and Australia. Ursula McGovern's co-authors include Constantine Alifrangis, Mark Linch, Thomas Powles, Alex Freeman, Eric W.‐F. Lam, Ana Gomes, Andreas Polychronis, R. Charles Coombes, Jun Wang and Jimmy M-M. Kwok and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and British Journal of Dermatology.

In The Last Decade

Ursula McGovern

14 papers receiving 456 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ursula McGovern United Kingdom 7 303 149 126 101 85 15 459
Priyanka Tibarewal United Kingdom 7 425 1.4× 72 0.5× 94 0.7× 39 0.4× 71 0.8× 11 486
Leili Ran United States 6 237 0.8× 75 0.5× 44 0.3× 137 1.4× 37 0.4× 10 497
Aldo Germani Italy 9 231 0.8× 63 0.4× 43 0.3× 40 0.4× 61 0.7× 22 363
Chenqi Lu China 13 471 1.6× 54 0.4× 76 0.6× 47 0.5× 230 2.7× 28 622
Tiepeng Li China 11 149 0.5× 219 1.5× 32 0.3× 55 0.5× 85 1.0× 37 428
Kyle M. LaPak United States 6 187 0.6× 113 0.8× 21 0.2× 63 0.6× 55 0.6× 11 353
Sabrina Klotz Germany 4 251 0.8× 115 0.8× 25 0.2× 43 0.4× 76 0.9× 4 547
Xianli He China 10 242 0.8× 142 1.0× 52 0.4× 96 1.0× 143 1.7× 19 469
Weiyuan Wei China 13 264 0.9× 133 0.9× 42 0.3× 74 0.7× 197 2.3× 19 413

Countries citing papers authored by Ursula McGovern

Since Specialization
Citations

This map shows the geographic impact of Ursula McGovern's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ursula McGovern with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ursula McGovern more than expected).

Fields of papers citing papers by Ursula McGovern

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ursula McGovern. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ursula McGovern. The network helps show where Ursula McGovern may publish in the future.

Co-authorship network of co-authors of Ursula McGovern

This figure shows the co-authorship network connecting the top 25 collaborators of Ursula McGovern. A scholar is included among the top collaborators of Ursula McGovern based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ursula McGovern. Ursula McGovern is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
1.
2.
Smith, Matthew R., Josep M. Piulats, Tilman Todenhöfer, et al.. (2024). CYCLONE 2: A phase 3 study of abemaciclib with abiraterone in patients with metastatic castration-resistant prostate cancer.. Journal of Clinical Oncology. 42(16_suppl). 5001–5001. 8 indexed citations
3.
Crabb, Simon J., Syed A. Hussain, Samantha Hinsley, et al.. (2022). A randomized, double blind, biomarker selected, phase II clinical trial of maintenance PARP inhibition following chemotherapy for metastatic urothelial carcinoma (mUC): Final analysis of the ATLANTIS rucaparib arm.. Journal of Clinical Oncology. 40(6_suppl). 436–436. 17 indexed citations
4.
Jones, Robert J., Syed A. Hussain, Alison Birtle, et al.. (2022). A randomised, double blind, phase II clinical trial of maintenance cabozantinib following chemotherapy for metastatic urothelial carcinoma (mUC): Final analysis of the ATLANTIS cabozantinib comparison.. Journal of Clinical Oncology. 40(17_suppl). LBA4505–LBA4505. 5 indexed citations
5.
Ng, Kenrick, Ursula McGovern, Myria Galazi, et al.. (2020). Febrile neutropenia (FN) rates in metastatic hormone sensitive prostate cancer: the role of antibiotics as primary prophylaxis. Prostate Cancer and Prostatic Diseases. 24(1). 166–168. 1 indexed citations
6.
7.
Alifrangis, Constantine, Ursula McGovern, Alex Freeman, Thomas Powles, & Mark Linch. (2019). Molecular and histopathology directed therapy for advanced bladder cancer. Nature Reviews Urology. 16(8). 465–483. 133 indexed citations
8.
Raison, Nicholas, Ursula McGovern, John Hines, & Dimitrios Volanis. (2019). Mixed adenoneuroendocrine carcinoma of the urethra. BMJ Case Reports. 12(3). e227948–e227948. 1 indexed citations
9.
Mateo, Joaquı́n, Núria Porta, Ursula McGovern, et al.. (2019). TOPARP-B: A phase II randomized trial of the poly(ADP)-ribose polymerase (PARP) inhibitor olaparib for metastatic castration resistant prostate cancers (mCRPC) with DNA damage repair (DDR) alterations.. Journal of Clinical Oncology. 37(15_suppl). 5005–5005. 36 indexed citations
10.
Mateo, Joaquı́n, Suzanne Carreira, George Seed, et al.. (2018). Genomic profiling of primary prostate tumors from patients who develop metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 36(15_suppl). 5013–5013. 4 indexed citations
11.
Harper, Alex, Mark Linch, Rowan Miller, et al.. (2016). Split dose gemcitabine/ cisplatin (GC) in urothelial carcinoma of the bladder: Review of toxicity and response.. Journal of Clinical Oncology. 34(15_suppl). e16018–e16018. 1 indexed citations
12.
Ho, Ka-Kei, Victoria A. McGuire, Chuay-Yeng Koo, et al.. (2011). Phosphorylation of FOXO3a on Ser-7 by p38 Promotes Its Nuclear Localization in Response to Doxorubicin. Journal of Biological Chemistry. 287(2). 1545–1555. 117 indexed citations
13.
McGovern, Ursula, et al.. (2010). Intracellular calcium as a second messenger following growth stimulation of human keratinocytes. British Journal of Dermatology. 132(6). 892–896. 5 indexed citations
14.
McGovern, Ursula, Richard E. Francis, Barrie Peck, et al.. (2009). Gefitinib (Iressa) represses FOXM1 expression via FOXO3a in breast cancer. Molecular Cancer Therapeutics. 8(3). 582–591. 115 indexed citations
15.
Essafi, Abdelkader, Ana Gomes, Karen M. Pomeranz, et al.. (2008). Studying the Subcellular Localization and DNA-Binding Activity of FoxO Transcription Factors, Downstream Effectors of PI3K/Akt. Methods in molecular biology. 462. 1–11. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Priyanka Tibarewal Breakdown of academic impact, for papers by Leili Ran Breakdown of academic impact, for papers by Aldo Germani Breakdown of academic impact, for papers by Chenqi Lu Breakdown of academic impact, for papers by Tiepeng Li Breakdown of academic impact, for papers by Kyle M. LaPak Breakdown of academic impact, for papers by Sabrina Klotz Breakdown of academic impact, for papers by Xianli He Breakdown of academic impact, for papers by Weiyuan Wei
Rankless by CCL
2026